CD14在脓毒症中的最新进展

Recent advances of CD14 in sepsis

脓毒症临床表现多样,是创伤、烧伤、感染、休克等临床危急重患者的常见严重并发症,其发病率和死亡率一直居高不下。前期研究发现,脂多糖结合蛋白(lipopolysaccharide binding protein,LBP)和白细胞分化抗原CD14(Leukocyte differentiation antigen,CD14)通过识别革兰阴性杆菌产生的内毒素,在脓毒症的发病过程中起关键作用。本文通过综合分析CDl4在脓毒症中的致病机理,探讨其在脓毒症诊断及治疗中的潜在临床价值。

Sepsis is a life-threatening disease responsible for high morbidity and mortality, which is initiated by varying conditions including trauma, burn and infection. Studies have revealed that lipopolysaccharide binding protein （LBP） and Leukocyte differentiation-14 antigen （CD14） recognize lipopolysaccharide （LPS） of gram-negative bacteria and trigger inflammatory response, playing a fundamental role in the development of sepsis. This review focuses on the role of CD14 in pathogenesis of sepsis and suggests that CD14 may be used as a potential biomarker for diagnosis and treatment of sepsis.